Cardio3 snaps up valve access business

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

The Belgian biotechnology company Cardio3 BioSciences acquired a device maker that specializes in heart access technologies for an undisclosed amount.

CorQuest is developing technologies that facilitate access directly to a patient's left atrium for treating mitral valve disorders and structural heart disease. The technologies allow cardiac surgeons to use a minimally invasive approach to deliver existing therapeutic devices. Cardio3 BioSciences sees the technology as complementary to its catheter and sheath delivery platforms.

The technology has yet to be approved in Europe or the U.S. The companies have a target date of late 2016 to obtain CE mark.

CorQuest also offers a line of medical devices and implants for treating structural heart diseases.

Cardio3 BioSciences is based in Mont-Saint-Guibert and CorQuest is in Miami.

Candace Stuart, Contributor

Related Content

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Hydra TAVR valve gains key approval as global reach continues to grow
SAVR outperforms TAVR in patients with bicuspid aortic valves
Treating AFib patients with TAVR still linked to elevated risks
Heart surgeons detail world’s first robotic heart procedure of its kind
Years of progress have made TAVR more effective when treating concomitant mitral stenosis

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.